TCHP antibody Polyclonal Antibodies Primary antibodies
- Known as:
- TCHP (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100712
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- TCHP antibody Polyclonal Antibodies Primary antibodies
Related genes to: TCHP antibody Polyclonal Antibodies Primary antibodies
- Gene:
- TCHP NIH gene
- Name:
- trichoplein keratin filament binding
- Previous symbol:
- -
- Synonyms:
- MGC10854, TpMs
- Chromosome:
- 12q24.11
- Locus Type:
- gene with protein product
- Date approved:
- 2006-01-27
- Date modifiied:
- 2016-03-14
Related products to: TCHP antibody Polyclonal Antibodies Primary antibodies
Related articles to: TCHP antibody Polyclonal Antibodies Primary antibodies
- Sepsis is a life-threatening complication in breast cancer patients undergoing chemotherapy, particularly when compounded by anorectal conditions. The management of eroded mixed hemorrhoids in the setting of severe chemotherapy-induced neutropenia and septicemia presents a clinical dilemma, as standard surgical interventions carry prohibitive risks. This case report details a successful conservative, multimodal approach to this rare and critical scenario. - Source: PubMed
Ye ZiXie HongmeiLan XiaoqianWang QiuzhouFu Lan - Anthracycline-free TCHP and anthracycline-based AC-THP are both used as neoadjuvant dual anti-HER2 regimens for HER2-positive breast cancer, but direct comparisons accounting for HER2 immunohistochemistry (IHC) intensity are lacking. Because IHC 3+ tumors respond substantially better to dual blockade, any between-group imbalance in IHC intensity can bias observational comparisons. - Source: PubMed
Publication date: 2026/09/22
Sharaf BahaTamimi FarisAlzoubi MohammadJawarneh QutaibaIsmail AmeenGhanem AmeedAta Jinan BaniAjlouni BatoolKhader RnadJaffal AdelKhater SuhaibJehad SharifAbdel-Razeq Hikmat - Structural modifications to tridentate NON ligands have been shown to play a key role in controlling the outcomes of group 2 metal diamide reduction reactions. Herein, two bulky, geometrically flexible diamines, NONH (NONH = O{2-N(H)Ar-4-BuCH}; Ar = 2,4,6-PrCH (Trip); 2,4,6-CyCH (TCHP)), have been synthesised. Treatment of NONH with one equivalent of either BePh, Mg{CH(SiMe)}, or Ca{N(SiMe)} in methylcyclohexane yielded group 2 metal diamide complexes. In the solid-state, monomeric [Be(NON)] features a T-shaped beryllium geometry, whereas the magnesium and calcium analogues [{Ae(NON)}] (Ae = Mg or Ca) are dimeric with distinct aggregation modes in the solid state. Although the strontium and barium counterparts could not be isolated, their treatment with THF led to structurally characterised [Ae(NON)(THF)] (Ae = Sr, = 3; Ae = Ba, = 4). Analogous deprotonations of the super-bulky NONH pro-ligand in toluene afforded donor-free [Be(NON)], the toluene adduct complexes, [Ae(NON)(PhMe)] (Ae = Mg, Ca), and the N-bridged dimeric barium system, [{Ba(NON)}]. Potassium reductions of these group 2 metal diamides led to a variety of outcomes, including reductive ligand C-O cleavage processes, yielding K[Mg{OCHBu-4-N(Trip)-2}{CHBu-4-N(Trip)-2}{Mg(NON)}], K[Be{OCHBu-4-N(TCHP)-2}{N(TCHP)(CHBu-3)}], possible O activation giving trace yields of [K{Mg(NON)}(μ-O)], and metal hydride formation solvent hydrogen abstraction, leading to [K{Ca(NON)(μ-H)}]. All of these reduction reactions are thought to proceed transient, reactive metal(I) radical species K[Ae(NON)˙]. - Source: PubMed
Publication date: 2026/09/29
Nguyen Dat TCzernetzki CorinnaParr Joseph MJones Cameron - Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced breast cancer, yet the molecular predictors of pathological response remain incompletely defined, particularly regarding microRNA (miRNA) dynamics. We investigated paired pre- and post-NAC miRNA expression profiles in relation to molecular subtype, residual cancer burden (RCB), and clinical timing parameters. Seven patients with invasive breast cancer (Luminal A = 3, Luminal B = 1, TNBC = 2, HER2+ = 1) who received NAC (AC-T or TCHP) were included in this pilot study. Small-RNA sequencing (NovaSeq X Plus, CeGaT GmbH, project S17293) was performed on 14 FFPE specimens (7 pre-NAC core needle biopsies, 7 post-NAC surgical specimens). Differential expression analysis used the paired Wilcoxon signed-rank test with Benjamini-Hochberg correction. Spearman correlations assessed associations between miRNA expression, RCB score, and clinical timing intervals. Candidate miRNAs were subsequently annotated using experimentally validated miRNA-target interactions. After filtering (≥ three counts in ≥ three samples), 759 miRNAs were analysed. No miRNA reached strict significance (adj < 0.05, |logFC| > 1.0) after multiple testing correction, consistent with the limited statistical power ( = 7). Under exploratory criteria ( < 0.10, |logFC| > 0.5), 156 candidate miRNAs were identified: 70 upregulated and 86 downregulated post-NAC. Leading candidates included hsa-miR-139-3p (+2.60), hsa-miR-139-5p (+2.36), and hsa-miR-1323 (+1.55) as upregulated, and hsa-miR-429 (-2.53), hsa-miR-141-3p (-1.79), and hsa-miR-1277-5p (-1.25) as downregulated post-NAC. The single patient achieving the lowest residual disease burden (P3, Luminal B, RCB-I, score 1.32) displayed a distinct pre-treatment miRNA profile, separating from all other pre-NAC specimens on principal component analysis and characterised by higher baseline hsa-miR-139-3p/-5p and lower baseline hsa-miR-429 and hsa-miR-141-3p expression, suggesting that baseline miRNA expression patterns may contribute to differential chemotherapy response. RCB score showed a non-significant positive trend with post-NAC Ki-67 (ρ = +0.71, = 0.07). This pilot study identifies NAC-modulated candidate miRNAs in breast cancer and establishes a paired FFPE-based small-RNA-sequencing workflow applicable in routine clinical settings. The distinct pre-treatment profile of the single best responder generates the testable hypothesis that baseline expression of tumour suppressor miRNAs of the miR-139 family, together with low miR-200-family expression, may track chemosensitivity. As no candidate reached statistical significance after multiple testing correction and none has been validated in an independent cohort or by an orthogonal method, all findings are exploratory and hypothesis-generating. The results support larger prospective validation studies examining miRNA signatures as predictive biomarkers of NAC response across breast cancer molecular subtypes. - Source: PubMed
Publication date: 2026/08/31
Komporaly Isabela AndaGheorghe Adelina SilvanaIovănescu Elena AdrianaGeorgescu BogdanStănculeanu Dana Lucia - Serpentine supravenous hyperpigmentation (SSH) is a rare dermatological complication of intravenous chemotherapy characterized by linear hyperpigmented streaks along superficial veins. Bullous SSH represents an exceptionally rare variant with only a few previously reported cases in the literature. We report the case of a 50-year-old woman with HER2-positive breast cancer who developed bullous SSH 5 days after her first cycle of TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) chemotherapy. The patient presented with linear erythematous streaks and small tense bullae along the infusion vein on her right forearm. Treatment with topical mometasone furoate 0.1% ointment resulted in complete resolution within 2 weeks. Preventive strategies described for SSH include use of contralateral arm venous access, thorough saline flushing after chemotherapy infusion, consideration of central venous access when feasible, and, in selected cases, modification of the chemotherapy regimen. In our patient, subsequent chemotherapy cycles were administered using contralateral arm venous access with thorough saline flushing (same flushing protocol as Cycle 1), without recurrence of SSH. The patient completed all six planned cycles and subsequently achieved pathologic complete response. This case is the first to demonstrate that conservative management of bullous SSH with topical mometasone furoate, combined with contralateral venous access and thorough saline flushing, enables successful rechallenge and uninterrupted continuation of planned oncological treatment with pathologic complete response as the outcome. - Source: PubMed
Publication date: 2026/08/21
Nair Gayathri RKoutsis JamesPoels DeepaliAgar NitaWarrier SanjayKumar Sanjeev